FindMyKOL

Ravinder Wali, MD

Basic profile

UMass Memorial Health Care

ORCIDNone on fileNPIOn fileSign in to see identifiers
RegionWorcester, MA · NortheastSpecialtyNephrologyFocusNephrology
Last active 2023FindMyKOL typeFindMyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Ravinder Wali is a Nephrology physician affiliated with UMass Memorial Health Care. OpenAlex indexes 44 publications with 3,101 citations (h-index 22); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
44publications

Publications indexed by OpenAlex. Counts exclude supporting files.

3,101citations

Citations across these publications.

22h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
3companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Veloxis Pharmaceuticals, Inc.
    Program year20231 payment
    $45
  • Mallinckrodt Hospital Products Inc.
    Program year20212 payments
    $67
  • Vifor Pharma, Inc.
    Program year20211 payment
    $43

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    46.6%
    Beta blocker14.2%
    Carvedilol42%Labetalol Hcl29%Metoprolol Succinate18%Metoprolol Tartrate12%
    Part D<11 patients
    Calcium channel blocker11.4%
    Amlodipine Besylate100%
    Part D≥23 patients

    + 7 more classes in this area

  • Metabolism & gastrointestinal

    31.9%
    Proton pump inhibitor9.3%
    Pantoprazole Sodium76%Omeprazole24%
    Part D<11 patients
    Corticosteroid7.3%
    Prednisone100%
    Part D≥15 patients

    + 5 more classes in this area

  • Anti-infectives

    6.7%
    Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor4.1%
    Valganciclovir Hcl100%
    Part D<11 patients
    Short-acting sulfonamides2.5%
    Sulfamethoxazole-Trimethoprim100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”